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Abstract 
Review on myeloid sarcoma, with data on clinics, 
pathology, and involved genes. 
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Extramedullary myeloid tumor 
Clinics and pathology 
Disease 
Myeloid sarcoma is defined as a proliferation of 
myeloblasts effacing tissue architecture and forming 
a mass in a site other than bone marrow.  Originally 
termed "chloroma" due to the greenish hue 
appreciated grossly owing to the production of 
myeloperoxidase, it has also been called 
granulocytic sarcoma (due to immature to maturing 
granulocytes, usually consistent with an acute 
myeloid leukemia with maturation, French-
American-British subtype M2), and extramedullary 
myeloid tumor.  In skin, this entity has been referred 
to as leukemia cutis.  However, the most recent and 
most encompassing term is myeloid sarcoma; while 
this entity can consist of myeloblasts (with or 
without maturation), it can also consist of 
monoblasts or myelomonocytes, and rarely erythroid 
precursors or megakaryoblasts. 
Phenotype/cell stem origin 
The cells of origin are hematopoietic stem 
cells/progenitor cells. 
Etiology 
The etiology of myeloid sarcoma is similar to that of 
acute myeloid leukemia, but instead is present in an 
extramedullary site. 
Epidemiology 
Myeloid sarcoma can occur at any age, but does 
appear more frequent in children and in older 
patients.  Some reports give a slightly increased male 
predominance (Pileri et al., 2007; Kawamoto et al., 
2016). Myeloid sarcoma is thought to occur in 1.4-
9% of patients with AML (Alexiev et al., 2007).  In 
children, the rate of isolated myeloid sarcoma is 
approximately 1.3%, while the rate of isolated 
myeloid sarcoma preceding AML is approximately 
2.5% (Reinhardt and Creutzig, 2002).  Myeloid 
sarcoma occurs in 6.7%-23.3% of children with a 
concurrent diagnosis of AML (Dusenbery et al., 
2003; Johnston et al., 2012; Stve et al., 2017). 
Clinics 
Myeloid sarcoma is thought to occur in four different 
scenarios: 1) de novo in the absence of any 
underlying acute myeloid leukemia or other myeloid 
neoplasm; 2) concurrently with acute myeloid 
leukemia (sometimes the first sign of disease); 3) 
representing blast crisis or blast transformation in 
myeloproliferative disorders or  myelodysplastic 
syndromes; 4) representing relapse AML (often 
post-transplant).  The latter scenario occurs in 5-12% 
of patients after allogeneic stem cell transplantation, 
accounting for 7-46% of post-transplant AML 
relapses (Solh et al., 2016). Approximately 27% of 
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patients present with de novo/isolated disease (Pileri 
et al., 2007).  Some reports have identified myeloid 
sarcoma in patient with concurrent non-Hodgkin's 
lymphoma or with a history of a non-hematopoietic 
tumor (Pileri et al., 2007).  
Myeloid sarcoma can occur anywhere in the body 
(except for the bone marrow), but has been found to 
be most frequent in the skin, lymph nodes, bone, soft 
tissue, gastrointestinal tract, and mediastinum, with 
less frequent sites including the testes (Traweek et 
al., 1993; Pileri et al., 2007; Kawamoto et al., 2016).  
Multiple sites of involvement may occur in the same 
individual at the same time. In children, the orbit is 
an additional common site (Reinhardt and Creutzig, 
2002; Dusenbery et al., 2003; Johnston et al., 2012; 
Støve et al., 2017).  
Symptoms of myeloid sarcoma depend on the site of 
involvement. 
Cytology 
As stated previously, the cells can be myeloblasts, 
differentiating granulocytes (ex. promyelocytes), a 
mixture of myeloblasts and monoblasts, pure 
monoblasts, or cells with monocytic differentiation.  
Rarely myeloid sarcomas consist of erythroblasts or 
megakaryoblasts.  The cells are usually medium to 
large in size with high nuclear-to-cytoplasmic ratios, 
fine to vesicular chromatin, variably prominent 
nucleoli, and scant cytoplasm which may contain 
granules.  Nuclei with irregular or indented contours 
may represent monocytic cells. 
Pathology 
By definition, myeloid sarcoma consists of blasts 
forming a mass in extramedullary tissue.  Depending 
on the tissue, the cells may be present in confluent 
sheets, nests, or in cords divided by fibrous septae.  
In lymph nodes, they can efface the architecture or 
be present infiltrating the paracortex and sinuses.  In 
the spleen, the neoplasm usually infiltrates the red 
pulp with persistent white pulp.  In some cases, 
eosinophilic myelocytes and a variety of granulocyte 
precursors can be seen intermixed with the blasts.  
The blasts may accumulate around blood vessels and 
may even invade blood vessel walls.  Mitoses may 
be readily identifiable and tingible body 
macrophages may be present.  Of note, in those cases 
with isolated myeloid sarcoma, bone marrow blasts 
may be present at  
By morphology, the sarcoma can usually be 
classified as acute myeloid leukemia with 
maturation, acute myelomonocytic leukemia, or 
acute monoblastic/monocytic leukemia. The 
myeloid sarcomas of the skin are often 
myelomonocytic or monoblastic/monocytic  
(Reinhardt and Creutzig, 2002; Pileri et al., 2007). 
Those in the orbit in pediatrics are often acute 
myeloid leukemia with maturation. 
 
Figure 1:  Leukemia cutis, or myeloid sarcoma of the skin.  
Left panel is low power magnification and right panel is high 
power magnification demonstrating an infiltrate of atypical 
cells with round to irregular nuclear contours, fine 
chromatin, conspicuous nucleoli, and pale cytoplasm. 
 
Treatment 
The treatment for myeloid sarcoma is the same as 
that for acute myeloid leukemia, which includes 
induction systemic chemotherapy (Bakst et al., 
2011).  Cytogenetic and molecular data are 
important for risk stratification, similar to AML.  For 
those with intermediate or high risk disease, 
allogeneic transplant may be considered (Solh et al., 
2016).  
Local radiation has not been found to be beneficial 
in induction therapy, but has been useful in 
consolidation if a complete response has not been 
achieved with chemotherapy.  Radiation may also be 
of use in situations where debulking or rapid 
symptom relief from compression are needed prior 
to induction chemotherapy, or when there is 
recurrence after transplant.  Surgery could also be 
performed if rapid debulking is required. (Bakst et 
al., 2011) 
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Figure 2:  Soft tissue mass demonstrating a proliferation of 
immature myeloid cells into adipose tissue.  Scattered 
eosinophilic myelocytes are also present in this myeloid 
sarcoma with t(8;21).  The middle panel demonstrates 
immunohistochemical staining for myeloperoxidase which is 
positive.  The right panel demonstrates positivity for CD117 
immunohistochemical staining. 
 
Figure 3:  Biopsy of soft tissue near the left knee 
demonstrates an infiltrate of medium sized cells with 
irregular nuclear contours, open chromatin, variably 
prominent nucleoli, and eosinophilic cytoplasm. 
Immunohistochemical staining for lysozyme is positive 
(second panel).  This myeloid sarcoma represented an 
extramedullary relapse after transplantation in a patient with 
AML with KMT2A gene rearrangement (MLL on 
chromosome 11q23). 
Treatment 
The treatment for myeloid sarcoma is the same as 
that for acute myeloid leukemia, which includes 
induction systemic chemotherapy (Bakst et al., 
2011). Cytogenetic and molecular data are important 
for risk stratification, similar to AML.  For those 
with intermediate or high risk disease, allogeneic 
transplant may be considered (Solh et al., 2016).  
Local radiation has not been found to be beneficial 
in induction therapy, but has been useful in 
consolidation if a complete response has not been 
achieved with chemotherapy.  Radiation may also be 
of use in situations where debulking or rapid 
symptom relief from compression are needed prior 
to induction chemotherapy, or when there is 
recurrence after transplant.  Surgery could also be 
performed if rapid debulking is required. (Bakst et 
al., 2011) 
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Evolution 
If isolate myeloid sarcoma is not treated, it will 
usually evolve into acute myeloid leukemia within 5 
to 12 months. 
Prognosis 
In patients with concurrent AML, the additional 
clinical finding of myeloid sarcoma has not been 
found to have clinical significance (Traweek et al., 
1993; Kawamoto et al., 2016).  A possible exception 
is in adult patients with the t(8;21) translocation in 
which myeloid sarcoma associated with leukemia 
has a worse prognosis than the leukemia alone (Byrd 
et al., 1997).  However, in children, isolated myeloid 
sarcoma has been found to have better prognosis 
than similarly aged children with acute myeloid 
leukemia (Dusenbery et al., 2003).  Additionally, 
children with orbital myeloid sarcoma have a higher 
overall survival compared to myeloid sarcoma from 
other sites, even after adjustment for cytogenetics 
(Johnston et al., 2012).  
In adults, studies have varied, with some 
demonstrated increased survival, others worse 
survival, and others no change in outcomes of 
isolated myeloid sarcoma cases compared to acute 
myeloid leukemia not associated with myeloid 
sarcoma (Wilson and Medeiros, 2015); however, 
two studies did show increased overall survival for 
those with isolated myeloid sarcoma (Tsimberidou et 
al., 2008; Movassaghian et al., 2015).  Kawamoto et 
al. (2016) found that those with myeloid sarcoma 
representing blast crisis or blast transformation in 
myeloproliferative disorders or myelodysplastic 
syndromes have a worse prognosis than myeloid 
sarcoma with or without concurrent AML. 
Cytogenetics 
Cytogenetics morphological 
Studies have shown that approximately 55% of cases 
have karyotypic abnormalities (Pileri et al., 2007).  
Similar to acute myeloid leukemia, myeloid sarcoma 
can have recurrent genetic abnormalities, including 
t(8;21)(q22;q22.1) ( RUNX1 / RUNX1T1), 
inv(16)(p13.1q22) ( CBFB / MYH11), and KMT2A 
(11q23) gene rearrangements.  Other karyotypic 
abnormalities include monosomy 7 and trisomy 8.  
Those with t(8;21) are more often located in the orbit 
and associated with pediatric cases; these cases 
represent acute myeloid leukemia with maturation 
(Reinhardt and Creutzig, 2002).  Cases with inv(16) 
tend to involve the intestine, breast, or uterus and are 
also associated with foci of plasmacytoid dendritic 
cells (Pileri et al., 2007).  Cases with KMT2A 
translocations more often involve the skin or breast, 
and are usually myelomonocytic or 
monoblastic/monocytic in morphology.  Those with 
t(9;22)(q34.1;q11.2) ( BCR / ABL1) are associated 
with chronic myelogenous leukemia in blast phase, 
and most commonly occur in lymph nodes (Wilson 
and Medeiros, 2015). 
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